Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200036/S010

eCoin Peripheral Neurostimulator

BOSTON SCIENTIFIC CORPORATION · Decision date Mar 3, 2026

FDA DECISIONP200036/S010

What did the FDA approve?

FDA records P200036/S010 as a supplement to PMA P200036, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Mar 3, 2026.

FDA approval order statement

Approval for protocol revisions which clarified the definition of subject enrollment and updates to the Schedule of Activities table regarding follow-up phone calls and clarification of protocol-unrelated standards of clinical care.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Gastroenterology, Urology
Decision date
Mar 3, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P200036/S010
Regulatory pathway
PMA supplement
Product code
QPT
Decision code
APPR
Decision date
Mar 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, tibial, electrical, implantable, for urinary incontinence.

Product code
QPT
FDA device class
3

For the original device and its historical approval scope, see PMA P200036. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200036 · Original PMA

    eCoin Peripheral Neurostimulator

  2. P200036/S009 · Related supplement

    eCoin Tibial Nerve Stimulator System

  3. P200036/S010 received

    Application receipt date recorded by FDA.

  4. P200036/S010 · FDA decision

    Normal 180 Day Track No User Fee

  5. P200036/S011 · Related supplement

    eCoin Peripheral Neurostimulator

  6. P200036/S012 · Related supplement

    eCoin Peripheral Neurostimulator

Timeline entries are records held by MedtechLedger for P200036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200036

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA approvalMar 1, 2022FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 2, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 20, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementSep 9, 2026FDA

Explore the linked device profile

Other records with product code QPT

Product / regulatory recordCompanyPathwayDecision dateSource
AltavivaP240011/S016
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA
AltavivaP240011/S015
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
AltavivaP240011/S010
Medtronic NeuromodulationPMA supplementJul 13, 2026FDA
AltavivaP240011/S014
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
AltavivaP240011/S013
Medtronic NeuromodulationPMA supplementMay 13, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
100 Boston Scientific Way, Marlborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records